Hilary Kramer
The Medicinal Edge
It’s been a long and somber year for cannabis investors. The recreational market simply hasn’t grown as anyone hoped, raising serious questions about stocks that depended on rapid expansion to support their multiples. The losses have been staggering. Aurora Cannabis Inc. (NYSE:ACB) is down 85% over the past year, and rival would-be giant Tilray Corp. […]
Canopy Falters
The last few weeks have been good for “Big Cannabis,” so we were poised for a correction. Canopy Growth Corp. (NYSE:CGC) gave us the signal. Nobody seriously thought the giant of the industry would make money. Profitability is still months, if not years, away. But to make the margins work, even CGC needs to grow […]
Who Sold in May With So Much Cash on the Sidelines?
I spend a lot of time comparing notes with other Wall Street strategists. We’re all obsessed with diagnosing what’s happened in the market in order to anticipate where we want to go. The best ones agree with me: if you’re already in U.S. stocks, you’re in the right place. There’s zero reason to sell right […]
CANNABIS CORNER: AURORA MAKES ITS MOVE
Aurora Cannabis Corp. (NYSE:ACB) is poised to benefit from the looming cannabis industry consolidation and we now have data to show that the prediction I previously made is coming true. ACB just issued $40 million in stock to buy its way into the U.S. cannabidiol (CBD) market. The acquisition in question, a company called Reliva, […]
Whatever Happened to the COVID-19 Crash?
Now that wide swathes of the country are opening up again for the summer, a lot of investors are still holding their breath and waiting for the final economic toll. The market, however, is already ahead of them. The NASDAQ is up a healthy 6% so far this year and is now once again within […]
Cannabis Corner: Aurora Turns It Around
Hilary Kramer discusses how Aurora, a big cannabis company, managed to turn its state of business around despite the market downturn.